AngioDynamics (ANGO) PT, Estimates Cut at Piper Jaffray Following 'Tough' Qtr
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Canaccord Genuity are Buyers of AngioDynamics (ANGO) on Weakness
April 10, 2015 9:55 AM EDTCanaccord Genuity analyst Jason Mills lowered his price target on AngioDynamics (NASDAQ: ANGO) to $20.00 (from $22.00) following soft Q3 results but maintained a Buy rating. The firm would be buyers on weakness.
Mills commented, "We would be buyers on weakness associated with soft FQ3 results and downward revision to guidance. On the heels of several consecutive quarters of solid execution, including expanding top-line growth and GM, a confluence of factors negatively impacted the business in F3Q, driving revenue below expectations. A few of these challenges were out of ANGOs control (negative foreign... More
AngioDynamics (ANGO) Misses Q3 EPS by 4c, Lowers FY15 Guidance
April 9, 2015 4:04 PM EDTAngioDynamics (NASDAQ: ANGO) reported Q3 EPS of $0.12, $0.04 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $86.6 million versus the consensus estimate of $89.8 million.
AngioDynamics sees FY2015 EPS of $0.57-$0.60, may not compare to the consensus of $0.68. AngioDynamics sees FY2015... More
